Entwicklung und Validierung des Stapesplasty Outcome Test 25 (SPOT-25)

Background: Otosclerosis affects health-related quality of life (HRQOL). Until now, measurements have only been performed using audiometric data or non-validated quality of life questionnaires.ObjectiveThe objective of this study was to develop the first validated disease-specific HRQOL measuring in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Lailach, Susen (VerfasserIn) , Baumann, Ingo (VerfasserIn) , Walter, Hannah (VerfasserIn) , Praetorius, Mark (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Deutsch
Veröffentlicht: 17 July 2017
In: HNO
Year: 2017, Jahrgang: 65, Heft: 12, Pages: 973-980
ISSN:1433-0458
DOI:10.1007/s00106-017-0389-x
Online-Zugang:Verlag, Volltext: http://dx.doi.org/10.1007/s00106-017-0389-x
Verlag, Volltext: https://doi.org/10.1007/s00106-017-0389-x
Volltext
Verfasserangaben:S. Lailach, T. Schenke, I. Baumann, H. Walter, M. Praetorius, T. Beleites, T. Zahnert, M. Neudert
Beschreibung
Zusammenfassung:Background: Otosclerosis affects health-related quality of life (HRQOL). Until now, measurements have only been performed using audiometric data or non-validated quality of life questionnaires.ObjectiveThe objective of this study was to develop the first validated disease-specific HRQOL measuring instrument to determine HRQOL in otosclerosis. Materials and methods: After sequential analysis and item reduction of the initial Stapesplasty Outcome Test 47 (SPOT-47), the SPOT-25 was validated prospectively on 52 otosclerosis patients undergoing stapes surgery. In addition to the overall score, four subscores were defined (hearing function, tinnitus, social restrictions, mental condition). Results: The SPOT-25 showed a high internal consistency (Cronbach’s α > 0.7), allowed discrimination between otosclerosis patients and healthy subjects, and demonstrated acceptable test-retest reliability (r = 0.85). After stapes surgery, the HRQOL improved significantly. The responsiveness was high. Conclusion: The SPOT-25 is the first validated disease-specific instrument for HRQOL measurement in otosclerosis patients. It should be used routinely for quality control.
Beschreibung:Gesehen am 25.10.2018
Beschreibung:Online Resource
ISSN:1433-0458
DOI:10.1007/s00106-017-0389-x